ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "etanercept"

  • Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting

    Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis

    Josef S. Smolen1, Ronald F. van Vollenhoven2, Andrew S. Koenig3, Ronald Pedersen3, Annette Szumski4 and Eustratios Bananis4, 1Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, 3Specialty Care, Pfizer Inc, Collegeville, PA, 4Specialty Care, Pfizer Inc., Collegeville, PA

    Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
  • Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting

    Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission

    Heather Jones1, Annette Szumski2 and Andrew S. Koenig3, 1Pfizer Inc., Collegeville, PA, 2Specialty Care, Pfizer Inc., Collegeville, PA, 3Specialty Care Business Unit, Pfizer Inc., Collegeville, PA

    Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
  • Abstract Number: 2002 • 2012 ACR/ARHP Annual Meeting

    Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?

    Petra C.E. Hissink Muller1, Bahar Yildiz1, Cornelia F. Allaart2, Danielle M.C. Brinkman3, Marion A. J. Van Rossum4, J. Merlijn Van den Berg5, Lisette W.A. Van Suijlekom-Smit6, Rebecca Ten Cate1 and Martine C. de Vries7, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 5Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, 6Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, 7Medical Ethics and Health Law, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: It is an ethical requirement for setting up a randomized controlled trial (RCT) that the physician-investigator must have genuine uncertainty about the therapeutic options.…
  • Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting

    Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population

    Vernon F. Schabert1, Crystal Watson2, George Joseph2, Paige Iversen1, Chakkarin Burudpakdee1 and David J. Harrison2, 1IMS Health, Alexandria, VA, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
  • Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting

    Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance

    Machaon Bonafede1, Crystal Watson2, George Joseph2, Nicole Princic1 and David J. Harrison2, 1Thomson Reuters Healthcare, Cambridge, MA, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
  • Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting

    Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms

    Paul Emery1, Piotr Wiland2, Wolfgang Spieler3, Jean Dudler4, Stefanie Gaylord5, Theresa Williams5, Ronald Pedersen5, Andrew S. Koenig5, Bonnie Vlahos5 and Sameer Kotak6, 1Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, 2Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, 3Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 4Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, 5Department of Specialty Care, Pfizer Inc., Collegeville, PA, 6Department of Specialty Care, Pfizer Inc., New York, NY

    Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
  • Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting

    When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry

    Maria Victoria Hernández1, Miguel A. Descalzo2, Juan D. Cañete1, Raimon Sanmarti3 and BIOBADASER Study Group4, 1Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Research Unit. Spanish Society of Rheumatology, Madrid, Spain

    Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
  • Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results

    Anjali Patwardhan1, Kelly A. Rouster-Stevens2, Harry L. Gewanter3, Grant D. Syverson4, Renee F. Modica5, Kara M. Schmidt6 and Charles H. Spencer7, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, 3Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, 4Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 5Pediatric Rheumatology, University of Florida, Gainesville, FL, 6Pediatric Rheumatology, Univ of Louisville, Louisville, KY, 7Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders.  Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology